查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1862186

植物药：全球市场份额和排名、总收入和需求预测（2025-2031 年）

Botanical Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 104 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球植物药市场预计在 2024 年达到 369.21 亿美元，预计到 2031 年将达到 490.76 亿美元，在预测期（2025-2031 年）内以 4.3% 的复合年增长率增长。

植物药是指源自天然植物或其活性成分，并经现代药学科学、生产过程和临床研究开发的治疗产品。与合成化学药物相比，植物药具有天然来源、成分复杂、作用机制多标靶等特点，融合了传统医学理论与现代科学成果。这包括符合国际监管标准的中药製剂和植物来源植物药。植物药应用广泛，涵盖慢性病管理、抗感染治疗、心血管疾病治疗、肿瘤治疗及免疫调节等领域。其研发和生产严格遵循GMP规范和先进的品管体系，以确保产品的一致性、有效性和安全性。近年来，在消费者对天然健康解决方案日益增长的偏好以及精准医疗兴起的推动下，植物药已成为全球医药市场的重要组成部分，并获得了政策支持和投资者的广泛关注。

在监管支持和市场需求的双重推动下，全球植物药产业蓬勃发展。世界各地的监管机构正致力于制定草药註册标准和药典规范，加速植物药的全球化进程。日益增强的健康意识和消费者对天然疗法的偏好创造了巨大的市场潜力。随着人口老化和慢性病的盛行率上升，植物药在心血管疾病管理、糖尿病治疗以及癌症康復等方面发挥重要作用。跨国製药公司的资本投入和积极参与推动了创新，而标准化萃取技术、活性成分分析和智慧製造技术的进步则加速了植物药的商业化和国际市场扩张。

儘管前景光明，植物药产业仍面临诸多挑战，包括复杂的临床检验、漫长的监管核准流程以及品质标准不一致等。植物来源的复杂性要求企业在研发和品管方面投入巨资，尤其要满足美国食品药物管理局 (FDA) 和欧洲药品管理局 (EMA) 的严格核准标准。智慧财产权保护依然是一大难题，仿冒品会影响品牌声誉和市场诚信。原料成本易受环境和气候因素影响，导致供应链不稳定。日益严格的监管和贸易壁垒迫使企业在合规、研发和市场拓展方面投入巨资，从而提高了市场进入门槛。

全球消费者对天然、永续和个人化医疗保健解决方案日益增长的偏好，正在推动植物药市场的发展。製药公司正迅速开发标准化的植物製剂，同时拓展机能性食品和保健产品领域。植物药在医院、药局和线上销售管道越来越受欢迎，尤其是在慢性病照护、癌症治疗辅助和健康疗法方面。跨境电商和全球行销策略正在协助具有独特文化特色的植物药品牌走向国际市场。此外，数位健康平台、产品溯源系统和个人化医疗正在推动植物药从传统治疗方法转型为现代精准医疗解决方案。

植物药的生产依赖多种药用植物资源，生产过程包括栽培、采收、加工和初级提取。先进的栽培技术和生态友善的采收方法对于确保稳定、高品质的供应链至关重要。对永续农业和良好农业规范（GAP）认证农场的日益重视，正在提升草药成分的可追溯性和品质一致性。随着气候变迁和保护政策限制了野生植物的收集，中国、印度和东南亚等地区兴起了大规模商业化种植，形成了全球供应基地。萃取和纯化技术的进步实现了成分的标准化，从而支持了高品质药物的研发和监管合规性。全球化的采购网络和现代化的物流基础设施使企业能够更好地应对季节性和波动性的市场需求。

本报告旨在按地区/国家、类型和应用对全球植物药市场进行全面分析，重点关注总销售额、市场份额和主要企业的排名。

本报告以收益为准，对植物药市场规模、估算和预测进行了呈现，以2024年为基准年，并包含了2020年至2031年的历史数据和预测数据。报告运用定量和定性分析，帮助读者制定业务/成长策略，评估市场竞争格局，分析自身在当前市场中的地位，并就植物药相关业务做出明智的决策。

市场区隔

公司

  • Buchang Pharmaceuticals
  • China TCM
  • Tsumura
  • Schwabe
  • Tong Ren Tang
  • Jumpcan Pharmaceutical
  • Guangzhou Baiyunshan Pharmaceutical
  • Yunnan Baiyao
  • Tasly Holding Group
  • Bionorica Se
  • Huarun 999
  • Taiji
  • Weleda
  • Kwangdong
  • GW Pharmaceuticals

按类型分類的细分市场

  • 处方药
  • 非处方药

应用领域

  • 循环系统
  • 瘤
  • 呼吸系统
  • 其他的

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Botanical Drug was estimated to be worth US$ 36921 million in 2024 and is forecast to a readjusted size of US$ 49076 million by 2031 with a CAGR of 4.3% during the forecast period 2025-2031.

Botanical drugs are therapeutic products derived from natural plants or their active ingredients, developed through modern pharmaceutical science, manufacturing processes, and clinical research. Compared with synthetic chemical drugs, botanical drugs feature natural origins, complex compositions, and multi-target mechanisms, representing a fusion of traditional medicine theories and modern scientific advancements. They include both traditional herbal preparations and innovative botanical-based drugs that meet international regulatory standards, with applications spanning chronic disease management, anti-infective therapies, cardiovascular care, oncology, and immunomodulation. Their development and production strictly follow GMP guidelines and advanced quality control systems to ensure consistency, efficacy, and safety. In recent years, driven by consumer preference for natural health solutions and the rise of precision medicine, botanical drugs have emerged as a key segment of the global pharmaceutical market, attracting strong policy support and investor interest.

The global botanical drug industry is experiencing growth fueled by both regulatory support and market demand. Regulatory agencies worldwide are refining herbal medicine registration standards and pharmacopoeia specifications, accelerating the globalization of botanical drugs. Rising health awareness and consumer preference for natural therapies create vast market potential. With aging populations and increasing prevalence of chronic diseases, botanical drugs are playing a vital role in cardiovascular health, diabetes care, oncology recovery, and more. Capital investment and active participation by multinational pharmaceutical companies are driving innovation, while advances in standardized extraction, active compound analysis, and intelligent manufacturing are accelerating commercialization and international market expansion.

Despite promising prospects, the botanical drug sector faces significant hurdles, including complex clinical validation, lengthy regulatory approval processes, and inconsistent quality standards. The inherent complexity of plant-based formulations requires substantial investment in R&D and quality control, particularly to meet stringent FDA and EMA approval criteria. Intellectual property protection remains a challenge, with counterfeit products impacting brand reputation and market order. Raw material costs are sensitive to environmental and climatic factors, leading to supply chain instability. Stricter regulations and trade barriers further compel companies to invest heavily in compliance, R&D, and market expansion, raising barriers to entry.

Global consumers' growing preference for natural, sustainable, and personalized healthcare solutions is energizing the botanical drug market. Pharmaceutical companies are rapidly developing standardized botanical formulations while extending their reach into functional foods and health management products. Botanical drugs are gaining traction in hospitals, pharmacies, and online sales channels, particularly for chronic disease care, oncology support, and wellness therapies. Cross-border e-commerce and global marketing strategies are helping culturally distinctive botanical brands expand internationally. Additionally, digital health platforms, product traceability systems, and personalized medicine are shaping the transition of botanical drugs from traditional remedies to modern precision healthcare solutions.

The backbone of botanical drug manufacturing lies in diverse medicinal plant resources, with production involving cultivation, harvesting, processing, and primary extraction. Advanced cultivation methods and ecological harvesting practices have become essential for securing a stable, high-quality supply chain. Growing emphasis on sustainable farming and GAP-certified plantations has improved traceability and consistency of herbal materials. As wild harvesting faces constraints due to climate change and conservation policies, large-scale commercial cultivation has emerged in regions such as China, India, and Southeast Asia, forming global supply hubs. Progress in extraction and purification technologies is enabling standardized raw materials, supporting high-end drug development and regulatory compliance. A globalized sourcing network and modern logistics infrastructure now allow companies to better manage seasonal fluctuations and dynamic market demands.

This report aims to provide a comprehensive presentation of the global market for Botanical Drug, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Botanical Drug by region & country, by Type, and by Application.

The Botanical Drug market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Botanical Drug.

Market Segmentation

By Company

  • Buchang Pharmaceuticals
  • China TCM
  • Tsumura
  • Schwabe
  • Tong Ren Tang
  • Jumpcan Pharmaceutical
  • Guangzhou Baiyunshan Pharmaceutical
  • Yunnan Baiyao
  • Tasly Holding Group
  • Bionorica Se
  • Huarun 999
  • Taiji
  • Weleda
  • Kwangdong
  • GW Pharmaceuticals

Segment by Type

  • Prescription Drug
  • OTC

Segment by Application

  • Cardiovascular
  • Tumor
  • Respiratory System
  • Other

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Botanical Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Botanical Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Botanical Drug in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Botanical Drug Product Introduction
  • 1.2 Global Botanical Drug Market Size Forecast (2020-2031)
  • 1.3 Botanical Drug Market Trends & Drivers
    • 1.3.1 Botanical Drug Industry Trends
    • 1.3.2 Botanical Drug Market Drivers & Opportunity
    • 1.3.3 Botanical Drug Market Challenges
    • 1.3.4 Botanical Drug Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Botanical Drug Players Revenue Ranking (2024)
  • 2.2 Global Botanical Drug Revenue by Company (2020-2025)
  • 2.3 Key Companies Botanical Drug Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Botanical Drug Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Botanical Drug
  • 2.6 Botanical Drug Market Competitive Analysis
    • 2.6.1 Botanical Drug Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Botanical Drug Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Botanical Drug as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Prescription Drug
    • 3.1.2 OTC
  • 3.2 Global Botanical Drug Sales Value by Type
    • 3.2.1 Global Botanical Drug Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Botanical Drug Sales Value, by Type (2020-2031)
    • 3.2.3 Global Botanical Drug Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Cardiovascular
    • 4.1.2 Tumor
    • 4.1.3 Respiratory System
    • 4.1.4 Other
  • 4.2 Global Botanical Drug Sales Value by Application
    • 4.2.1 Global Botanical Drug Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Botanical Drug Sales Value, by Application (2020-2031)
    • 4.2.3 Global Botanical Drug Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Botanical Drug Sales Value by Region
    • 5.1.1 Global Botanical Drug Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Botanical Drug Sales Value by Region (2020-2025)
    • 5.1.3 Global Botanical Drug Sales Value by Region (2026-2031)
    • 5.1.4 Global Botanical Drug Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Botanical Drug Sales Value, 2020-2031
    • 5.2.2 North America Botanical Drug Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Botanical Drug Sales Value, 2020-2031
    • 5.3.2 Europe Botanical Drug Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Botanical Drug Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Botanical Drug Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Botanical Drug Sales Value, 2020-2031
    • 5.5.2 South America Botanical Drug Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Botanical Drug Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Botanical Drug Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Botanical Drug Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Botanical Drug Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Botanical Drug Sales Value, 2020-2031
    • 6.3.2 United States Botanical Drug Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Botanical Drug Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Botanical Drug Sales Value, 2020-2031
    • 6.4.2 Europe Botanical Drug Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Botanical Drug Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Botanical Drug Sales Value, 2020-2031
    • 6.5.2 China Botanical Drug Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Botanical Drug Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Botanical Drug Sales Value, 2020-2031
    • 6.6.2 Japan Botanical Drug Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Botanical Drug Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Botanical Drug Sales Value, 2020-2031
    • 6.7.2 South Korea Botanical Drug Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Botanical Drug Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Botanical Drug Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Botanical Drug Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Botanical Drug Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Botanical Drug Sales Value, 2020-2031
    • 6.9.2 India Botanical Drug Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Botanical Drug Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Buchang Pharmaceuticals
    • 7.1.1 Buchang Pharmaceuticals Profile
    • 7.1.2 Buchang Pharmaceuticals Main Business
    • 7.1.3 Buchang Pharmaceuticals Botanical Drug Products, Services and Solutions
    • 7.1.4 Buchang Pharmaceuticals Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Buchang Pharmaceuticals Recent Developments
  • 7.2 China TCM
    • 7.2.1 China TCM Profile
    • 7.2.2 China TCM Main Business
    • 7.2.3 China TCM Botanical Drug Products, Services and Solutions
    • 7.2.4 China TCM Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.2.5 China TCM Recent Developments
  • 7.3 Tsumura
    • 7.3.1 Tsumura Profile
    • 7.3.2 Tsumura Main Business
    • 7.3.3 Tsumura Botanical Drug Products, Services and Solutions
    • 7.3.4 Tsumura Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Tsumura Recent Developments
  • 7.4 Schwabe
    • 7.4.1 Schwabe Profile
    • 7.4.2 Schwabe Main Business
    • 7.4.3 Schwabe Botanical Drug Products, Services and Solutions
    • 7.4.4 Schwabe Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Schwabe Recent Developments
  • 7.5 Tong Ren Tang
    • 7.5.1 Tong Ren Tang Profile
    • 7.5.2 Tong Ren Tang Main Business
    • 7.5.3 Tong Ren Tang Botanical Drug Products, Services and Solutions
    • 7.5.4 Tong Ren Tang Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Tong Ren Tang Recent Developments
  • 7.6 Jumpcan Pharmaceutical
    • 7.6.1 Jumpcan Pharmaceutical Profile
    • 7.6.2 Jumpcan Pharmaceutical Main Business
    • 7.6.3 Jumpcan Pharmaceutical Botanical Drug Products, Services and Solutions
    • 7.6.4 Jumpcan Pharmaceutical Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Jumpcan Pharmaceutical Recent Developments
  • 7.7 Guangzhou Baiyunshan Pharmaceutical
    • 7.7.1 Guangzhou Baiyunshan Pharmaceutical Profile
    • 7.7.2 Guangzhou Baiyunshan Pharmaceutical Main Business
    • 7.7.3 Guangzhou Baiyunshan Pharmaceutical Botanical Drug Products, Services and Solutions
    • 7.7.4 Guangzhou Baiyunshan Pharmaceutical Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Guangzhou Baiyunshan Pharmaceutical Recent Developments
  • 7.8 Yunnan Baiyao
    • 7.8.1 Yunnan Baiyao Profile
    • 7.8.2 Yunnan Baiyao Main Business
    • 7.8.3 Yunnan Baiyao Botanical Drug Products, Services and Solutions
    • 7.8.4 Yunnan Baiyao Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Yunnan Baiyao Recent Developments
  • 7.9 Tasly Holding Group
    • 7.9.1 Tasly Holding Group Profile
    • 7.9.2 Tasly Holding Group Main Business
    • 7.9.3 Tasly Holding Group Botanical Drug Products, Services and Solutions
    • 7.9.4 Tasly Holding Group Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Tasly Holding Group Recent Developments
  • 7.10 Bionorica Se
    • 7.10.1 Bionorica Se Profile
    • 7.10.2 Bionorica Se Main Business
    • 7.10.3 Bionorica Se Botanical Drug Products, Services and Solutions
    • 7.10.4 Bionorica Se Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Bionorica Se Recent Developments
  • 7.11 Huarun 999
    • 7.11.1 Huarun 999 Profile
    • 7.11.2 Huarun 999 Main Business
    • 7.11.3 Huarun 999 Botanical Drug Products, Services and Solutions
    • 7.11.4 Huarun 999 Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Huarun 999 Recent Developments
  • 7.12 Taiji
    • 7.12.1 Taiji Profile
    • 7.12.2 Taiji Main Business
    • 7.12.3 Taiji Botanical Drug Products, Services and Solutions
    • 7.12.4 Taiji Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Taiji Recent Developments
  • 7.13 Weleda
    • 7.13.1 Weleda Profile
    • 7.13.2 Weleda Main Business
    • 7.13.3 Weleda Botanical Drug Products, Services and Solutions
    • 7.13.4 Weleda Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.13.5 Weleda Recent Developments
  • 7.14 Kwangdong
    • 7.14.1 Kwangdong Profile
    • 7.14.2 Kwangdong Main Business
    • 7.14.3 Kwangdong Botanical Drug Products, Services and Solutions
    • 7.14.4 Kwangdong Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.14.5 Kwangdong Recent Developments
  • 7.15 GW Pharmaceuticals
    • 7.15.1 GW Pharmaceuticals Profile
    • 7.15.2 GW Pharmaceuticals Main Business
    • 7.15.3 GW Pharmaceuticals Botanical Drug Products, Services and Solutions
    • 7.15.4 GW Pharmaceuticals Botanical Drug Revenue (US$ Million) & (2020-2025)
    • 7.15.5 GW Pharmaceuticals Recent Developments

8 Industry Chain Analysis

  • 8.1 Botanical Drug Industrial Chain
  • 8.2 Botanical Drug Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Botanical Drug Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Botanical Drug Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Botanical Drug Market Trends
  • Table 2. Botanical Drug Market Drivers & Opportunity
  • Table 3. Botanical Drug Market Challenges
  • Table 4. Botanical Drug Market Restraints
  • Table 5. Global Botanical Drug Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Botanical Drug Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Botanical Drug Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Botanical Drug Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Botanical Drug
  • Table 10. Global Botanical Drug Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Botanical Drug as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Botanical Drug Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Botanical Drug Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Botanical Drug Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Botanical Drug Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Botanical Drug Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Botanical Drug Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Botanical Drug Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Botanical Drug Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Botanical Drug Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Botanical Drug Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Botanical Drug Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Botanical Drug Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Botanical Drug Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Botanical Drug Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Botanical Drug Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Botanical Drug Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Botanical Drug Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Botanical Drug Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Buchang Pharmaceuticals Basic Information List
  • Table 32. Buchang Pharmaceuticals Description and Business Overview
  • Table 33. Buchang Pharmaceuticals Botanical Drug Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Botanical Drug Business of Buchang Pharmaceuticals (2020-2025)
  • Table 35. Buchang Pharmaceuticals Recent Developments
  • Table 36. China TCM Basic Information List
  • Table 37. China TCM Description and Business Overview
  • Table 38. China TCM Botanical Drug Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Botanical Drug Business of China TCM (2020-2025)
  • Table 40. China TCM Recent Developments
  • Table 41. Tsumura Basic Information List
  • Table 42. Tsumura Description and Business Overview
  • Table 43. Tsumura Botanical Drug Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Botanical Drug Business of Tsumura (2020-2025)
  • Table 45. Tsumura Recent Developments
  • Table 46. Schwabe Basic Information List
  • Table 47. Schwabe Description and Business Overview
  • Table 48. Schwabe Botanical Drug Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Botanical Drug Business of Schwabe (2020-2025)
  • Table 50. Schwabe Recent Developments
  • Table 51. Tong Ren Tang Basic Information List
  • Table 52. Tong Ren Tang Description and Business Overview
  • Table 53. Tong Ren Tang Botanical Drug Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Botanical Drug Business of Tong Ren Tang (2020-2025)
  • Table 55. Tong Ren Tang Recent Developments
  • Table 56. Jumpcan Pharmaceutical Basic Information List
  • Table 57. Jumpcan Pharmaceutical Description and Business Overview
  • Table 58. Jumpcan Pharmaceutical Botanical Drug Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Botanical Drug Business of Jumpcan Pharmaceutical (2020-2025)
  • Table 60. Jumpcan Pharmaceutical Recent Developments
  • Table 61. Guangzhou Baiyunshan Pharmaceutical Basic Information List
  • Table 62. Guangzhou Baiyunshan Pharmaceutical Description and Business Overview
  • Table 63. Guangzhou Baiyunshan Pharmaceutical Botanical Drug Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Botanical Drug Business of Guangzhou Baiyunshan Pharmaceutical (2020-2025)
  • Table 65. Guangzhou Baiyunshan Pharmaceutical Recent Developments
  • Table 66. Yunnan Baiyao Basic Information List
  • Table 67. Yunnan Baiyao Description and Business Overview
  • Table 68. Yunnan Baiyao Botanical Drug Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Botanical Drug Business of Yunnan Baiyao (2020-2025)
  • Table 70. Yunnan Baiyao Recent Developments
  • Table 71. Tasly Holding Group Basic Information List
  • Table 72. Tasly Holding Group Description and Business Overview
  • Table 73. Tasly Holding Group Botanical Drug Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Botanical Drug Business of Tasly Holding Group (2020-2025)
  • Table 75. Tasly Holding Group Recent Developments
  • Table 76. Bionorica Se Basic Information List
  • Table 77. Bionorica Se Description and Business Overview
  • Table 78. Bionorica Se Botanical Drug Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Botanical Drug Business of Bionorica Se (2020-2025)
  • Table 80. Bionorica Se Recent Developments
  • Table 81. Huarun 999 Basic Information List
  • Table 82. Huarun 999 Description and Business Overview
  • Table 83. Huarun 999 Botanical Drug Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Botanical Drug Business of Huarun 999 (2020-2025)
  • Table 85. Huarun 999 Recent Developments
  • Table 86. Taiji Basic Information List
  • Table 87. Taiji Description and Business Overview
  • Table 88. Taiji Botanical Drug Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Botanical Drug Business of Taiji (2020-2025)
  • Table 90. Taiji Recent Developments
  • Table 91. Weleda Basic Information List
  • Table 92. Weleda Description and Business Overview
  • Table 93. Weleda Botanical Drug Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Botanical Drug Business of Weleda (2020-2025)
  • Table 95. Weleda Recent Developments
  • Table 96. Kwangdong Basic Information List
  • Table 97. Kwangdong Description and Business Overview
  • Table 98. Kwangdong Botanical Drug Products, Services and Solutions
  • Table 99. Revenue (US$ Million) in Botanical Drug Business of Kwangdong (2020-2025)
  • Table 100. Kwangdong Recent Developments
  • Table 101. GW Pharmaceuticals Basic Information List
  • Table 102. GW Pharmaceuticals Description and Business Overview
  • Table 103. GW Pharmaceuticals Botanical Drug Products, Services and Solutions
  • Table 104. Revenue (US$ Million) in Botanical Drug Business of GW Pharmaceuticals (2020-2025)
  • Table 105. GW Pharmaceuticals Recent Developments
  • Table 106. Key Raw Materials Lists
  • Table 107. Raw Materials Key Suppliers Lists
  • Table 108. Botanical Drug Downstream Customers
  • Table 109. Botanical Drug Distributors List
  • Table 110. Research Programs/Design for This Report
  • Table 111. Key Data Information from Secondary Sources
  • Table 112. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Botanical Drug Product Picture
  • Figure 2. Global Botanical Drug Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Botanical Drug Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Botanical Drug Report Years Considered
  • Figure 5. Global Botanical Drug Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Botanical Drug Revenue in 2024
  • Figure 7. Botanical Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Prescription Drug Picture
  • Figure 9. OTC Picture
  • Figure 10. Global Botanical Drug Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 11. Global Botanical Drug Sales Value Market Share by Type, 2024 & 2031
  • Figure 12. Product Picture of Cardiovascular
  • Figure 13. Product Picture of Tumor
  • Figure 14. Product Picture of Respiratory System
  • Figure 15. Product Picture of Other
  • Figure 16. Global Botanical Drug Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 17. Global Botanical Drug Sales Value Market Share by Application, 2024 & 2031
  • Figure 18. North America Botanical Drug Sales Value (2020-2031) & (US$ Million)
  • Figure 19. North America Botanical Drug Sales Value by Country (%), 2024 VS 2031
  • Figure 20. Europe Botanical Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 21. Europe Botanical Drug Sales Value by Country (%), 2024 VS 2031
  • Figure 22. Asia Pacific Botanical Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. Asia Pacific Botanical Drug Sales Value by Region (%), 2024 VS 2031
  • Figure 24. South America Botanical Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. South America Botanical Drug Sales Value by Country (%), 2024 VS 2031
  • Figure 26. Middle East & Africa Botanical Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 27. Middle East & Africa Botanical Drug Sales Value by Country (%), 2024 VS 2031
  • Figure 28. Key Countries/Regions Botanical Drug Sales Value (%), (2020-2031)
  • Figure 29. United States Botanical Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 30. United States Botanical Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 31. United States Botanical Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 32. Europe Botanical Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 33. Europe Botanical Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 34. Europe Botanical Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 35. China Botanical Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 36. China Botanical Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 37. China Botanical Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 38. Japan Botanical Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 39. Japan Botanical Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 40. Japan Botanical Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 41. South Korea Botanical Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 42. South Korea Botanical Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 43. South Korea Botanical Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 44. Southeast Asia Botanical Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 45. Southeast Asia Botanical Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 46. Southeast Asia Botanical Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 47. India Botanical Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 48. India Botanical Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 49. India Botanical Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 50. Botanical Drug Industrial Chain
  • Figure 51. Botanical Drug Manufacturing Cost Structure
  • Figure 52. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 53. Bottom-up and Top-down Approaches for This Report
  • Figure 54. Data Triangulation
  • Figure 55. Key Executives Interviewed